South San Francisco, CA March 6, 2019 Genentech Press Release FDA Accepts Genentech’s Supplemental New Drug Application for Xofluza (baloxavir marboxil) for the Treatment of Influenza in People at High Risk of Complications — XOFLUZA would be the first antiviral…
Tag: Roche Group
Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer
South San Francisco, CA September 5, 2018 Press Release Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from its broad clinical development program across different types of lung cancer will be…
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
South San Francisco, CA August 28, 2017 Genentech Press Release SOUTH SAN FRANCISCO, CA — 2017-08-27 00:00:00 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has…
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
South San Francisco, CA July 10, 2017 Genentech Press Release Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87 percent…
Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) In People With Previously Treated Advanced Bladder Cancer
South San Francisco, CA May 10, 2017 Genentech Press Release — IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy — –The safety profile was consistent with what has been previously observed for TECENTRIQ–…
FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
South San Francisco, CA April 17, 2017 Press Release Genentech First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy — SOUTH SAN FRANCISCO, CA —…